Common Allergic Reactions to Lurbinectedin
Lurbinectedin (Zepzelca), used for small cell lung cancer, can trigger hypersensitivity reactions during or shortly after infusion. These typically occur in the first cycle and include rash, urticaria (hives), pruritus (itching), flushing, and swelling of the face or tongue.[1][2]
Severe Symptoms Requiring Immediate Action
Anaphylaxis or severe hypersensitivity may cause bronchospasm (wheezing), hypotension (low blood pressure), tachycardia (rapid heart rate), dyspnea (shortness of breath), and angioedema (swelling under the skin). Symptoms can appear within minutes to hours of administration.[1][3]
Premedication with corticosteroids, antihistamines, and H2 blockers reduces risk, but monitoring for at least 2 hours post-infusion is standard.[2]
How Reactions Are Graded and Managed
Reactions are graded by CTCAE criteria:
- Grade 1: Mild, transient rash or itching.
- Grade 2: Moderate symptoms like hives or mild bronchospasm; often managed with dose interruption.
- Grade 3-4: Life-threatening; requires permanent discontinuation.[1][3]
Permanent discontinuation is needed for Grade 3 or 4 events. Resuming after milder reactions involves slowing infusion rates.[2]
Risk Factors and Frequency
Reactions occur in about 5-10% of patients, higher in early cycles. Prior chemotherapy exposure increases likelihood. Patients with asthma or allergies may be at higher risk.[1][3]
Differences from Other Infusion Reactions
Unlike cytokine release syndrome (CRS) from CAR-T therapies, lurbinectedin reactions are IgE-mediated and resolve quickly with supportive care, without prolonged fever or organ damage.[2]
[1]: Zepzelca (lurbinectedin) Prescribing Information, Jazz Pharmaceuticals, https://www.zepzelca.com/pdf/zepzelca-prescribing-information.pdf
[2]: NCCN Guidelines for Small Cell Lung Cancer, Version 3.2024, https://www.nccn.org/guidelines
[3]: FDA Label for Zepzelca, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213069s000lbl.pdf